BASF urged to seize Evonik’s weakness via bold takeover bid
Executive summary: Handelsblatt published a commentary advocating for BASF to launch a takeover of Evonik, asserting the move is both bold and justified. Such a merger would reshape Europe's chemicals landscape, creating a larger entity better positioned to compete with US and Middle Eastern rivals.
Who is involved: BASF, Evonik, European chemical industry stakeholders, and potentially EU competition authorities.
Likely next: BASF may evaluate a formal offer; Evonik’s board and shareholders would assess any proposal; regulatory scrutiny would follow if transaction thresholds are met.
A Handelsblatt commentary has argued that BASF should take advantage of Evikon’s current weakness and launch a bold takeover bid, describing such a move as both courageous and correct. The piece notes that the suggestion comes amid rising competitive pressure from U.S. and Gulf‑based chemical producers and frames the potential deal as a way for European chemical consolidation to be driven by domestic players rather than foreign actors. While the commentary does not provide any concrete terms, timelines or board approvals, the mere prospect of a BASF‑Evonik combination has already prompted a noticeable reaction in the share prices of both companies, indicating that investors are sensitive to the idea of a major reshaping of the German chemical sector. If BASF were to pursue the acquisition, the implied rationale would be to achieve greater scale, potentially unlock cost synergies across research, production and logistics, and strengthen its position against low‑cost overseas competitors. However, any such transaction would also invite scrutiny from antitrust authorities given the combined market share the two firms hold in specialty chemicals, performance materials and agricultural solutions. The lack of disclosed financial details means that the potential impact on leverage, dividend policy or integration costs remains uncertain at this stage. In the near term, market participants are likely to watch for any formal statements from BASF’s management or board regarding due‑diligence activities, as well as for regulatory signals that could affect the feasibility of a deal. Until concrete steps are taken, the discussion remains speculative, but the heightened attention underscores the strategic importance of scale and competitiveness in the European chemicals landscape.
What's next — scenarios
BASF Initiates Exploratory M&A Talks (20%)
Chemical suppliers must prepare for significant portfolio rationalization and antitrust compliance reviews over the next 12 months.
- BASF or Evonik management issues an ad-hoc disclosure regarding merger discussions
- Activist investors take a notable stake in Evonik pushing for a sale
Evonik Restructures Independently (50%)
Competitive pressure in the European specialty chemicals market will persist, forcing smaller players to cut costs rather than consolidate.
- Evonik announces a major asset divestment or portfolio spin-off independent of BASF
- BASF publicly denies any interest in pursuing large-scale M&A in the near term
Foreign Private Equity Intervenes (30%)
European chemical assets face foreign acquisition, shifting competitive dynamics and supply chain access for industrial buyers.
- A private equity consortium submits a preliminary takeover proposal for Evonik
- Evonik management adopts defensive anti-takeover measures
What to watch
- Evonik quarterly earnings report and management commentary on portfolio strategy in the next 45 days
- BASF capital markets updates regarding M&A appetite and capital allocation priorities over the next 60 days
- Public statements by major Evonik shareholders regarding domestic versus foreign consolidation within the next 30 days
Timeline
- — Kommentar: BASF nutzt die große Schwäche von Evonik – und das ist gut so (Handelsblatt)
- — Evonik: Übernahmespekulationen durch BASF treiben Aktie deutlich an (Der Spiegel — Wirtschaft)
- — Chemie: BASF lotet Fusion mit Evonik aus – Aktien reagieren kräftig (Handelsblatt)
- — Chemie: BASF laut Bericht an Evonik-Übernahme interessiert – Aktien reagieren kräftig (Handelsblatt)
- — Chemiebranche: BASF laut Bericht an Evonik-Übernahme interessiert – Aktien reagieren kräftig (Handelsblatt)
Analysis — what this means
Sectors affected
- Specialty chemicals
- Basic chemicals
Key entities
Sources
- Kommentar: BASF nutzt die große Schwäche von Evonik – und das ist gut so — Handelsblatt
- Chemie: BASF lotet Fusion mit Evonik aus – Aktien reagieren kräftig — Handelsblatt
- Evonik: Übernahmespekulationen durch BASF treiben Aktie deutlich an — Der Spiegel — Wirtschaft
- Chemie: BASF laut Bericht an Evonik-Übernahme interessiert – Aktien reagieren kräftig — Handelsblatt
- Chemiebranche: BASF laut Bericht an Evonik-Übernahme interessiert – Aktien reagieren kräftig — Handelsblatt
Related cases
- DAX firms are cutting net debt sharply, building cash reserves to shield against rising interest rates
- BASF sues Apple for allegedly using its subsidiary trinamiX's facial recognition technology without permission, seeking damages and an injunction
- Solvay publishes its Q2 2026 results in a regulated press release
- BASF’s plan to spin off its agribusiness at a record valuation could unlock billions in shareholder value amid shifting market conditions
- BASF plans to spin off its agriculture division via a 2027 IPO targeting a €20‑30 bn valuation, potentially exceeding half of the group’s current market cap
- BASF’s planned 2027 spin‑off IPO of its agriculture business could revive Germany’s dormant IPO market and signal renewed investor confidence in large‑scale listings